ReviewFrontiers in pharmacology2022

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson's disease.

Vasanti Suvarna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.